Robert L. Fine

8.2k total citations · 1 hit paper
122 papers, 6.1k citations indexed

About

Robert L. Fine is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Robert L. Fine has authored 122 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 47 papers in Molecular Biology and 22 papers in Cancer Research. Recurrent topics in Robert L. Fine's work include Drug Transport and Resistance Mechanisms (22 papers), Pancreatic and Hepatic Oncology Research (20 papers) and Cancer Genomics and Diagnostics (16 papers). Robert L. Fine is often cited by papers focused on Drug Transport and Resistance Mechanisms (22 papers), Pancreatic and Hepatic Oncology Research (20 papers) and Cancer Genomics and Diagnostics (16 papers). Robert L. Fine collaborates with scholars based in United States, United Kingdom and Malaysia. Robert L. Fine's co-authors include Bruce A. Chabner, Elizabeth R. Gerstner, Alok A. Khorana, Clifford Sachs, Jeffrey N. Bruce, Jitendra Patel, John A. Chabot, Aejaz Nasir, James F. Helm and Dung‐Tsa Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Robert L. Fine

121 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

2010 519 citations Robert L. Fine et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert L. Fine United States	48	3.1k	2.4k	1.3k	833	802	122	6.1k
Anish Thomas United States	43	3.7k 1.2×	2.8k 1.2×	718 0.6×	636 0.8×	2.9k 3.6×	161	8.5k
Janet A. Houghton United States	46	3.0k 1.0×	4.3k 1.8×	569 0.4×	552 0.7×	795 1.0×	144	6.5k
Desmond N. Carney United States	38	4.5k 1.5×	4.1k 1.7×	2.3k 1.8×	812 1.0×	1.8k 2.2×	93	8.8k
Amit Maity United States	45	2.7k 0.9×	3.4k 1.4×	511 0.4×	310 0.4×	1.2k 1.5×	153	7.2k
Nam H. Dang United States	49	4.2k 1.4×	2.2k 0.9×	518 0.4×	265 0.3×	662 0.8×	194	7.6k
Richard B. Lock Australia	53	2.8k 0.9×	5.1k 2.1×	329 0.3×	1.0k 1.2×	952 1.2×	260	8.7k
Hal W. Hirte Canada	45	3.7k 1.2×	3.2k 1.3×	476 0.4×	280 0.3×	1.3k 1.6×	156	8.1k
Murray D. Norris Australia	46	3.1k 1.0×	4.8k 2.0×	500 0.4×	1.8k 2.2×	497 0.6×	197	8.2k
Patrick G. Morris United States	33	2.8k 0.9×	1.6k 0.7×	438 0.3×	418 0.5×	889 1.1×	136	5.2k
Niramol Savaraj United States	47	2.4k 0.8×	3.2k 1.3×	579 0.5×	242 0.3×	741 0.9×	211	6.9k

Countries citing papers authored by Robert L. Fine

Since Specialization

Citations

This map shows the geographic impact of Robert L. Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Fine more than expected).

Fields of papers citing papers by Robert L. Fine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Fine. The network helps show where Robert L. Fine may publish in the future.

Co-authorship network of co-authors of Robert L. Fine

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Fine. A scholar is included among the top collaborators of Robert L. Fine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Fine. Robert L. Fine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fine, Robert L., Yuehua Mao, Ramon Rosal, et al.. (2023). C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines. 11(1). 137–137.

Gulati, Anthony P., Stephen M. Schreibman, Beth Schrope, et al.. (2014). Prospective phase II study of inoperable pancreatic adenocarcinoma with neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX).. Journal of Clinical Oncology. 32(3_suppl). 274–274. 2 indexed citations

Le, Dung T., Andrea Wang‐Gillam, Vincent J. Picozzi, et al.. (2014). A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.. Journal of Clinical Oncology. 32(3_suppl). 177–177. 25 indexed citations

Mao, Yuehua, Wanglong Qiu, Nicholas Cassai, et al.. (2013). Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC. Molecular Cancer Therapeutics. 12(12). 2792–2803. 19 indexed citations

Gulati, Anthony P., et al.. (2012). Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature. Oncology. 84(3). 127–134. 6 indexed citations

Schönleben, Frank, John Allendorf, Wanglong Qiu, et al.. (2008). Mutational Analyses of Multiple Oncogenic Pathways in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas. 36(2). 168–172. 32 indexed citations

Balmaceda, Casilda, David M. Peereboom, Susan C. Pannullo, et al.. (2008). Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas. Cancer. 112(5). 1139–1146. 50 indexed citations

Drew, Lisa, Daniel P. Petrylak, Yuehua Mao, et al.. (2007). Activation of Targeted Necrosis by a p53 Peptide. Journal of Biological Chemistry. 282(37). 26675–26686. 16 indexed citations

Fine, Robert L., Johnson Chen, Casilda Balmaceda, et al.. (2006). Randomized Study of Paclitaxel and Tamoxifen Deposition into Human Brain Tumors: Implications for the Treatment of Metastatic Brain Tumors. Clinical Cancer Research. 12(19). 5770–5776. 55 indexed citations

10.

Fine, Robert L., Samir S. Shah, Thomas Moulton, et al.. (2006). Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemotherapy and Pharmacology. 59(4). 429–437. 30 indexed citations

11.

Kaufman, Howard L., et al.. (2005). Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. The Lancet Oncology. 6(1). 62–63. 5 indexed citations

12.

Li, Yin, Yuehua Mao, Ramon Rosal, et al.. (2005). Selective induction of apoptosis through the FADD/caspase‐8 pathway by a p53 c‐terminal peptide in human pre‐malignant and malignant cells. International Journal of Cancer. 115(1). 55–64. 25 indexed citations

13.

Rosal, Ramon, Lisa Drew, Anthony J. Raffo, et al.. (2003). Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene. 22(10). 1431–1444. 65 indexed citations

14.

Lee, Chang Woo, Dong Ho Hong, Sang‐Bae Han, et al.. (2002). A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. Biochemical Pharmacology. 64(3). 473–480. 54 indexed citations

15.

Chari, Ravi S., Feng‐Ming Kong, Jeremy Mills, et al.. (1995). Transforming Growth Factor-Beta Receptors and Mannose 6-Phosphate/Insulin-Like Growth Factor-II Receptor Expression in Human Hepatocellular Carcinoma. Annals of Surgery. 222(2). 171–178. 65 indexed citations

16.

Blobe, Gerard C., Clifford Sachs, Waris Khan, et al.. (1993). Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha.. Journal of Biological Chemistry. 268(1). 658–664. 155 indexed citations

17.

Surbone, Antonella, Harry Ford, James A. Kelley, et al.. (1990). Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).. PubMed. 50(4). 1220–5. 15 indexed citations

18.

Hayashi, Seiji, Robert L. Fine, Ting‐Chao Chou, et al.. (1990). In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrobial Agents and Chemotherapy. 34(1). 82–88. 39 indexed citations

19.

Allegra, C J, Robert L. Fine, J C Drake, & B A Chabner. (1986). ヒトMCF‐7乳がん細胞における細胞内葉酸プールに対するメトトレキセートの影響プリン合成の直接阻害の証拠. Journal of Biological Chemistry. 261(14). 6478–6485. 1 indexed citations

20.

Klecker, Raymond W., Jean Jenkins, Timothy J. Kinsella, et al.. (1985). Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clinical Pharmacology & Therapeutics. 38(1). 45–51. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact